DERM - Journey Medical Corp
IEX Last Trade
4.48
-0.705 -15.737%
Share volume: 0
Last Updated: Tue 24 Dec 2024 04:48:11 PM CET
Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology) :
-0.12%
PREVIOUS CLOSE
CHG
CHG%
$5.18
-0.71
-13.60%
Fundamental analysis
28%
Profitability
16%
Dept financing
48%
Liquidity
67%
Performance
25%
Performance
5 Days
-4.06%
1 Month
-21.78%
3 Months
-17.16%
6 Months
-9.84%
1 Year
-43.59%
2 Year
287.07%
Key data
Stock price
$4.48
DAY RANGE
$4.48 - $5.18
52 WEEK RANGE
$3.27 - $7.12
52 WEEK CHANGE
-$36.22
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
11/07/2024
Company detail
CEO: Claude Maraoui
Region: US
Website: journeymedicalcorp.com
Employees: 90
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
Sector: Professional, Scientific, and Technical Services
Region: US
Website: journeymedicalcorp.com
Employees: 90
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
Sector: Professional, Scientific, and Technical Services
Journey Medical Corporation focuses on the development and commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. The company's marketed products include Qbrexza, a medicated cloth towelette for the. treatment of primary axillary hyperhidrosis; Accutane, an oral isotretinoin drug to treat severe recalcitrant acne; Targadox, an. oral doxycycline drug for. adjunctive therapy for severe acne, Ximino, and Exelderm cream for topical use.
Recent news